Free Trial
→ Trump's Law S.1582: $21T Dollar Revolution Coming (From Brownstone Research) (Ad)tc pixel
NYSE:ANRO

Alto Neuroscience Q1 2024 Earnings Report

Alto Neuroscience logo
$6.87 +2.46 (+55.83%)
Closing price 10/3/2025 03:59 PM Eastern
Extended Trading
$7.25 +0.38 (+5.49%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Alto Neuroscience EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.46
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

Alto Neuroscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alto Neuroscience Announcement Details

Quarter
Q1 2024
Date
5/14/2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Alto Neuroscience's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Alto Neuroscience's Q1 2024 Press ReleasePress Release
(8-K)
Alto Neuroscience's Q1 2024 Quarterly reportQuarterly report
(10-Q)

Alto Neuroscience Earnings Headlines

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug
 |  msn.comhttps://www.msn.com/en-us/health/other/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-to-schizophrenia-drug/ar-AA1NOLal
Alto Neuroscience stock soars after FDA grants Fast Track designation
October 3 at 11:09 AM  |  investing.comhttps://www.investing.com/news/stock-market-news/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-93CH-4270742
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.tc pixel
 |  Weiss Ratings (Ad)
Alto Neuroscience granted fast track designation for ALTO-101
October 3 at 11:09 AM  |  msn.comhttps://www.msn.com/en-us/health/other/alto-neuroscience-granted-fast-track-designation-for-alto-101/ar-AA1NOgmU
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
October 3 at 11:01 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/03/3161044/0/en/Johnson-Fistel-PLLP-Investigates-Claims-on-Behalf-of-Alto-Neuroscience-Inc-Long-Term-Shareholders.html
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
October 3 at 7:34 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20251003096029/en/alto-neuroscience-receives-fda-fast-track-designation-for-alto-101-for-the-treatment-of-cognitive-impairment-associated-with-schizophrenia/
See More Alto Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications.

Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements.

As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.

View Alto Neuroscience Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles